Scinai Immunotherapeutics Ltd. financial data

Symbol
SCNI on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
Jerusalem Biopark, 2 Nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel
State of incorporation
Israel
Fiscal year end
December 31
Former names
BiondVax Pharmaceuticals Ltd. (to 8/28/2023)
Latest financial report
20-F - Q4 2023 - May 15, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.86B shares
Common Stock, Shares, Outstanding 3.35B shares +130%
Entity Public Float 16.7M USD
Weighted Average Number of Shares Outstanding, Basic 1.35B shares +81%
Weighted Average Number of Shares Outstanding, Diluted 1.35B shares +81%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.45M USD -26.3%
General and Administrative Expense 1.14M USD -11.5%
Operating Income (Loss) -2.6M USD +20.5%
Nonoperating Income (Expense) -1.17M USD -517%
Net Income (Loss) Attributable to Parent -3.76M USD -26.1%
Earnings Per Share, Basic 0 USD/shares 0%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.08M USD -59%
Accounts Receivable, after Allowance for Credit Loss, Current 119K USD
Other Assets, Current 437K USD +182%
Assets, Current 3.66M USD -52.9%
Property, Plant and Equipment, Net 10.2M USD -5.76%
Operating Lease, Right-of-Use Asset 1.01M USD -23.5%
Assets 14.9M USD -25.4%
Employee-related Liabilities, Current 388K USD -19.8%
Accrued Liabilities, Current 461K USD -39%
Liabilities, Current 1.67M USD -11.4%
Operating Lease, Liability, Noncurrent 640K USD -31%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.74M USD 0%
Retained Earnings (Accumulated Deficit) -127M USD -3.01%
Stockholders' Equity Attributable to Parent -7.28M USD -2.42%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -1.76M USD -279%
Liabilities and Equity 14.9M USD -25.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.06M USD -177%
Net Cash Provided by (Used in) Investing Activities -6K USD +98.8%
Common Stock, Shares Authorized 20B shares 0%
Common Stock, Shares, Issued 3.35B shares +130%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.29M USD -65.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.21M USD -57.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 725K USD
Deferred Tax Assets, Valuation Allowance 26.4M USD +18.2%
Operating Lease, Liability 420K USD
Payments to Acquire Property, Plant, and Equipment 6K USD -98.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3.61M USD
Property, Plant and Equipment, Gross 13.6M USD -0.24%
Operating Lease, Liability, Current 364K USD -7.61%
Deferred Tax Assets, Operating Loss Carryforwards 26.1M USD +20.4%
Additional Paid in Capital 121M USD +3%
Depreciation, Depletion and Amortization 138K USD +2.99%
Deferred Tax Assets, Net of Valuation Allowance 26.2M USD +19%
Share-based Payment Arrangement, Expense 252K USD -48%